Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2011 Jul 25;3(3):3018–3028. doi: 10.3390/cancers3033018

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2011 by the authors; licensee MDPI, Basel, Switzerland.

This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).

PMC Copyright notice

Figure 3. — Detouring the road to H. pylori-associated carcinogenesis through alleviating gastric inflammation. (A) In spite of IARC definition that H. pylori infection is class I carcinogen, more than 80% among population infected with H. pylori remains asymptomatic, about which no clear explanation has not been forwarded. On the other hand, H. pylori infection is apparently associated with the emergence of precancerous lesion and some gastric malignancy. Host genetic polymorphisms, environmental factors, H. pylori strains, and host immune response might affect the outcome, but the common fact is that chronic gastric inflammation is the fundamental basis for H. pylori-associated gastric carcinogenesis. (B) Multiple lines of evidence had suggested the detouring the unpleasant journey to H. pylori-associated gastric carcinogenesis seems to be the effective strategy to prevent H. pylori-associated gastric cancer, for which COX-2 inhibitor, antioxidants, anti-inflammatory drug, phytoceuticals, and others had been documented.